Phase 1/2 CROP Trial Reports 78% Five-Year Survival With SBRT and Intermittent ADT
Mature results from the Phase 1/2 CROP trialshow encouraging long-term outcomes in men with oligometastatic hormone-sensitive prostate cancer treated with stereotactic body radiotherapy (SBRT) and intermittent androgen deprivation therapy (ADT). At five years, overall survival reached 78.2%, while 22.8% of patients had developed castration-resistant disease.
The prospective, single-arm study included 89 patients with up to five metastatic lesions, including 33 with metastases at initial diagnosis and 56 whose metastatic disease developed after earlier treatment. Researchers delivered SBRT to all known tumor sites, including the prostate when appropriate, and administered 12 months of ADT. Hormonal treatment was then discontinued, with the possibility of restarting it following disease progression or a substantial PSA increase.
After a median follow-up of 74.7 months, the five-year cumulative incidence of new metastases was 56.1%, while local failure at previously irradiated sites remained relatively uncommon, at 8.8%. Five-year failure-free survival was 15.2%, reflecting the fact that many patients eventually required additional treatment despite favorable overall survival.
An important finding was that 39.3% of patients were alive without receiving ADT at their final assessment, although some had undergone additional treatment during follow-up. The five-year cumulative incidence of restarting ADT was 59.7%, and testosterone recovery reached 82.9% at three years.
PSA response also appeared to carry prognostic information. The median PSA nadir was just 0.03 ng/mL, and approximately 81% of patients achieved a nadir of 0.2 ng/mL or lower. Higher PSA nadirs were associated with greater risks of developing castration-resistant disease and reduced overall survival.
The treatment was generally manageable, although six patients (6.7%) experienced grade 3 radiation-related adverse events, including five vertebral fractures and one urinary obstruction.
These findings highlight the potential of combining comprehensive metastasis-directed radiotherapy with planned breaks from hormonal therapy in carefully selected patients.

Leave a Reply
Want to join the discussion?Feel free to contribute!